Trial Profile
An open label, pilot and expansion pharmacodynamic Study of (Z)-endoxifen in Patients with Invasive Breast Cancer Prior to Undergoing Mastectomy or Lumpectomy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2021
Price :
$35
*
At a glance
- Drugs Endoxifen (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Sponsors Atossa Therapeutics
- 09 Jun 2021 Primary endpoint (To assess the effect of pre-operative oral (Z)-Endoxifen treatment on clinical response measured by Ki67 expression levels. Ki67 will be assessed via tumor biopsy analysis.) has been met, according to an Atossa Therapeutics Media Release.
- 09 Jun 2021 Final results published in an Atossa Therapeutics Media Release.
- 07 Jun 2021 According to an Atossa Therapeutics media release, the company announces that it will hold a webinar at 8 am Pacific Time on June 9, 2021 to release and discuss final data from this study.